Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FGMCNASDAQ:KLDONASDAQ:STIXNASDAQ:VRAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFGMCFG Merger$9.67$9.59$9.53▼$9.85$25.10MN/A48,799 shs17,140 shsKLDOKaleido Biosciences$0.00$0.00$0.00▼$0.07$85K-0.069,255 shsN/ASTIXSemantix$0.00$0.28▼$4.77$23.73M-0.3752,087 shsN/AVRARThe Glimpse Group$1.19+3.0%$1.18$0.50▼$7.00$25.04M1.09814,953 shs77,694 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFGMCFG Merger0.00%+0.62%+0.83%+250.36%+779.09%KLDOKaleido Biosciences0.00%-60.00%-95.00%+1,900.00%+1,900.00%STIXSemantix0.00%0.00%0.00%0.00%-99.69%VRARThe Glimpse Group+3.03%+4.39%-0.83%-30.00%+1.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFGMCFG MergerN/AN/AN/AN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ASTIXSemantixN/AN/AN/AN/AN/AN/AN/AN/AVRARThe Glimpse Group3.0961 of 5 stars3.55.00.00.03.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFGMCFG Merger 0.00N/AN/AN/AKLDOKaleido Biosciences 0.00N/AN/AN/ASTIXSemantix 0.00N/AN/AN/AVRARThe Glimpse Group 3.00Buy$2.62120.17% UpsideCurrent Analyst Ratings BreakdownLatest KLDO, FGMC, STIX, and VRAR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/8/2025VRARThe Glimpse GroupWestpark CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$4.67 ➝ $2.622/14/2025VRARThe Glimpse GroupWestpark CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.67 ➝ $4.67(Data available from 5/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFGMCFG MergerN/AN/AN/AN/AN/AN/AKLDOKaleido Biosciences$1.10M0.08N/AN/AN/A∞STIXSemantix$264.23M0.00N/AN/A$1.01 per share0.00VRARThe Glimpse Group$9.23M2.71N/AN/A$0.85 per share1.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFGMCFG MergerN/AN/A0.00∞N/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/A-$2.24N/AN/AN/AN/AN/AN/AN/ASTIXSemantix-$63.61M-$0.81N/AN/AN/A-69.49%-45.45%-26.98%N/AVRARThe Glimpse Group-$6.39M-$0.39N/A∞N/A-70.68%-47.08%-35.47%5/21/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFGMCFG MergerN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AN/ASTIXSemantixN/AN/AN/AN/AN/AVRARThe Glimpse GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFGMCFG MergerN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/ASTIXSemantixN/A1.611.61VRARThe Glimpse GroupN/A2.542.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFGMCFG MergerN/AKLDOKaleido Biosciences81.56%STIXSemantix40.12%VRARThe Glimpse Group21.41%Insider OwnershipCompanyInsider OwnershipFGMCFG Merger20.20%KLDOKaleido Biosciences9.00%STIXSemantix35.50%VRARThe Glimpse Group21.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFGMCFG Merger22.60 millionN/ANot OptionableKLDOKaleido Biosciences8042.62 million38.79 millionNot OptionableSTIXSemantix479.10 million51.02 millionNot OptionableVRARThe Glimpse Group20021.04 million16.53 millionOptionableKLDO, FGMC, STIX, and VRAR HeadlinesRecent News About These CompaniesTrip.com: Labor Day Surge Gives A Glimpse Into Its Growth TrajectoryApril 30 at 7:04 AM | seekingalpha.comGlimpse Group’s Brightline Interactive delivers immersive simulator to U.S. NavyApril 23, 2025 | markets.businessinsider.comBrightline Interactive Successfully Delivers First Full-Motion Immersive Simulator to the U.S. NavyApril 22, 2025 | accessnewswire.comThe Glimpse Group, Inc. (NASDAQ:VRAR) Q2 2025 Earnings Call TranscriptFebruary 17, 2025 | insidermonkey.comGlimpse Group (NASDAQ:VRAR) Is In A Good Position To Deliver On Growth PlansFebruary 15, 2025 | finance.yahoo.comThe Glimpse Group outlines $11M+ FY2025 revenue target with strong Q4 projectionsFebruary 13, 2025 | seekingalpha.comThe Glimpse Group, Inc. (VRAR) Q2 2025 Earnings Call TranscriptFebruary 13, 2025 | seekingalpha.comThe Glimpse Group Reports Q2 Fiscal Year 2025 Financial Results - 50% Increase in Revenue and Positive EBITDA, Positive Cash Flow & Positive Net IncomeFebruary 13, 2025 | accessnewswire.comThe Glimpse Group to Announce Q2 Fiscal Year 2025 Financial Results On Thursday, February 13, 2025 at 9am Eastern TimeFebruary 7, 2025 | accessnewswire.comIs The Glimpse Group (VRAR) the Best Augmented Reality Stock to Invest in Under $10?February 4, 2025 | msn.comGlimpse President and CEO Lyron Bentovim To Be Interviewed on Schwab Network’s “Trading 360 ...January 17, 2025 | bakersfield.comGlimpse President and CEO Lyron Bentovim To Be Interviewed on Schwab Network's “Trading 360 with Nicole Petallides” On The Topic of Immersive Technology, Spatial Computing, AI and Key PartnershipsJanuary 17, 2025 | globenewswire.comThe Glimpse Group IncJanuary 9, 2025 | morningstar.comWhy Is Glimpse Group Inc (VRAR) Stock Surpassing 120.91% from Its 50-Day SMA?January 3, 2025 | bovnews.comGlimpse Group Inc (VRAR) Stock: Understanding Its Underlying ValueDecember 28, 2024 | bovnews.comWinning In The Spatial Computing, AI and Cloud Immersive Segment - A Glimpse Group Webinar On X Spaces, hosted by WOLF Financial (Tuesday, December 31, 2024 at 1:00pm EST)December 27, 2024 | accesswire.comGlimpse Group regains compliance with NasdaqDecember 24, 2024 | markets.businessinsider.comThe Glimpse Group Regains Compliance with NASDAQDecember 24, 2024 | accesswire.comGlimpse Group Inc (VRAR) Stock: Unveiling Its Hidden StrengthsDecember 24, 2024 | bovnews.comGlimpse Group Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)December 24, 2024 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKLDO, FGMC, STIX, and VRAR Company DescriptionsFG Merger NASDAQ:FGMC$9.67 0.00 (0.00%) As of 05/2/2025 03:59 PM EasternFG Merger II Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on September 20, 2023 and is headquartered in Itasca, IL.Kaleido Biosciences NASDAQ:KLDO$0.0020 0.00 (0.00%) As of 05/2/2025Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Semantix NASDAQ:STIXSemantix, Inc., together with its subsidiaries, provides end-to-end proprietary Software as a Service (SaaS) data platform in Latin America and the United States. The company offers SDP, a multi-cloud SaaS data platform that provides data integration, data operations, machine learning operations, data governance, data sharing, and data visualization for financial institutions; healthcare plans operators, health insurance brokers, hospitals, clinics, and imaging and diagnostics facilities; and retailers. It also sells third-party software licenses to the finance, retail, telecommunications, healthcare, industrials, and other sectors. In addition, the company offers artificial intelligence and data analytics services, including consulting, cloud monitoring, data integration, data science, and data engineering. The company was founded in 2010 and is based in São Paulo, Brazil.The Glimpse Group NASDAQ:VRAR$1.19 +0.04 (+3.03%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$1.18 -0.01 (-0.84%) As of 05/2/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The Glimpse Group, Inc., a virtual reality (VR) and augmented reality (AR) platform company, provides enterprise-focused software, services, and solutions in the United States. It offers QReal, a software that creates and distributes photorealistic 3D interactive digital models and experiences in AR; Immersive Health Group, a VR/AR platform for evidence-based and outcome driven healthcare solutions; and Foretell Reality, a social VR platform for behavioral health, support groups, collaboration, and soft skills training. The company also provides Glimpse Turkey for developing and creating 3D models for QReal; XR Terra that provides immersive technologies for teaching courses and training; Sector 5 Digital for corporate immersive experiences and events; PulpoAR, an AR try-on technology that targets the beauty and cosmetics industry; and Brightline Interactive, which offers immersive and interactive experiences, training scenarios, and simulations for government and commercial customers. The company was incorporated in 2016 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/28 - 05/02 Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious Meta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Why Spotify Stock Still Has Room to Run in 2025 Is It Time to Load Up on Bond ETFs? Palantir Earnings: 1 Bullish Signal and 1 Area of Concern Roblox Stock Gains Momentum and Can Top $100 in 2025 Visa Q2 Earnings Top Forecasts, Adds $30B Buyback Plan Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
